Evidence map›Paper›PMID 29734365›Full record

ArticlePloS one2018

Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform.

Sara A Bumgardner, Lin Zhang, Alora S LaVoy, Barbara Andre, Chad B Frank, Akinobu Kajikawa, Todd R Klaenhammer, Gregg A Dean

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. M2b macrophage polarization and its roles in diseases.Journal of leukocyte biology · 2019
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara A BumgardnerCenter for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America.
Lin ZhangDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America.
Alora S LaVoyDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America.
Barbara AndreDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America.ORCID 0000-0002-4221-1979
Chad B FrankDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America.
Akinobu KajikawaDepartment of Applied Biology and Chemistry, Tokyo University of Agriculture, Setagaya, Tokyo, Japan.
Todd R KlaenhammerDepartment of Food, Bioprocessing, & Nutrition Sciences, North Carolina State University, Raleigh, North Carolina, United States of America.
Gregg A DeanDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America.ORCID 0000-0001-7025-9550

Funding

Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1R01DE019069 · NIDCR · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI DEAN, GREGG A · 2008 to 2012
$1.9M
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPERR21AI112486 · NIAID · COLORADO STATE UNIVERSITY · PI DEAN, GREGG A · 2014 to 2015
$409k
NIAID NIH HHS R21 AI112486NIDCR NIH HHS R01 DE019069NIH HHS R01 DE019069NIH HHS R21 AI112486
6 · The paper itself

Abstract

Safe and efficacious orally-delivered mucosal vaccine platforms are desperately needed to combat the plethora of mucosally transmitted pathogens. Lactobacillus spp. have emerged as attractive candidates to meet this need and are known to activate the host innate immune response in a species- and strain-specific manner. For selected bacterial isolates and mutants, we investigated the role of key innate immune pathways required for induction of innate and subsequent adaptive immune responses. Co-culture of murine macrophages with L. gasseri (strain NCK1785), L. acidophilus (strain NCFM), or NCFM-derived mutants-NCK2025 and NCK2031-elicited an M2b-like phenotype associated with TH2 skewing and immune regulatory function. For NCFM, this M2b phenotype was dependent on expression of lipoteichoic acid and S layer proteins. Through the use of macrophage genetic knockouts, we identified Toll-like receptor 2 (TLR2), the cytosolic nucleotide-binding oligomerization domain containing 2 (NOD2) receptor, and the inflammasome-associated caspase-1 as contributors to macrophage activation, with NOD2 cooperating with caspase-1 to induce inflammasome derived interleukin (IL)-1β in a pyroptosis-independent fashion. Finally, utilizing an NCFM-based mucosal vaccine platform with surface expression of human immunodeficiency virus type 1 (HIV-1) Gag or membrane proximal external region (MPER), we demonstrated that NOD2 signaling is required for antigen-specific mucosal and systemic humoral responses. We show that lactobacilli differentially utilize innate immune pathways and highlight NOD2 as a key mediator of macrophage function and antigen-specific humoral responses to a Lactobacillus acidophilus mucosal vaccine platform.

Indexed as

Administration, OralAnimalsAntigensCaspase 1Genes, gagHIV-1HumansImmunity, HumoralInflammasomesInterleukin-1betaLactobacillus acidophilusLipopolysaccharidesMacrophagesMiceNod2 Signaling Adaptor ProteinTeichoic AcidsAntigensCaspase 1IL1B protein, mouseInflammasomesInterleukin-1betaLipopolysaccharideslipoteichoic acidNod2 protein, mouseNod2 Signaling Adaptor ProteinTeichoic AcidsTlr2 protein, mouseToll-Like Receptor 2Vaccines

Identifiers

PMID29734365
PMCPMC5937747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.